
|Videos|October 9, 2021
Faricimab for DME: Results of phase 3 YOSEMITE and RHINE trials
Author(s)OT Staff Reports, Sheryl Stevenson
Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.
Advertisement
Ophthalmology Times®' Sheryl Stevenson speaks with Caroline Baumal, MD, professor of ophthalmology, Tufts University School of Medicine; New England Eye Center (Boston, MA), on results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in diabetic macular edema (DME).
---
The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
3
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
4
iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland
5


























